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Abstract
Gastrointestinal stromal tumours (GIST) are rare tumours of mesenchymal origin. These can be associated with neuro-
fibromatosis type 1 (NF1), which is an autosomal dominant disorder. The prevalence of GIST in NF1 is estimated at
3.9–25%. This paper describes the presentation of a GIST arising from the jejenum in a 75-year-old lady with NF1, who
presented with gastrointestinal bleeding. This was diagnosed by CT angiography. She was managed with laparotomy,
with resection of small bowel, and an ischaemic segment of large bowel with two primary anastomoses. Pathology
showed GIST of spindle cell type (Figs 3 and 4), 90mm in size, with complete local excision. The patient was discharged
on the eighth post-operative day and is currently undergoing regular clinic follow-up after multidisciplinary team
meeting discussion.
INTRODUCTION
A 75-year-old lady presented with melaena and per rectum bleed-
ing and was found to have a gastrointestinal stromal tumour
(GIST) of the small intestine, on a background of neurofibroma-
tosis type 1 (NF1). During the same admission, this was success-
fully resected with two primary anastomoses. The patient was
discharged home on the eighth post-operative day.
This is a rare presentation of GIST in association with NF1.
Although this is a known association, cases are still rare in the
literature. It is important to consider GIST in the differential
diagnosis in patients with known NF1 presenting with abdom-
inal symptoms including GI bleeding.
CASE REPORT
This 75-year-old lady with a background of neurofibromatosis pre-
sented to the medical team with melaena and PR bleeding of both
altered and fresh blood, with intermittent generalized abdominal
pain. She has previously had an upper GI bleed in 2013 with upper
GI endoscopy which could not find a specific lesion, and a CT col-
onoscopy which showed no abnormality. Examination findings
revealed a soft abdomen with a palpable mass on the left-hand
side. Per rectal examination revealed was soft stool only.
She had an upper GI endoscopy which was unremarkable
and subsequently she was referred to the surgical team. She
had a CT angiogram and continued to have PR bleeding
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requiring blood transfusion. She underwent surgery with an
uneventful post-operative recovery and went home on the
eighth post-operative day.
Investigations
Haemoglobin—88 g/l (106 g/l 2 months prior to admission)
MCV—73.4 (fl)
Haematocrit—0.278 l/l
CRP—132mg/l
WCC—20.2 × 109/l
Erect AP chest X-ray—reported as normal
Abdominal X-ray—reported as normal
Upper GI endoscopy–hiatus hernia only
CT angiography (Figs 1 and 2)—large 9 cm exophytic cavitat-
ing lesion arising from jejunum with no evidence of active
haemorrhage, with multiple further lesions in the duodenum.
This was felt to be the source of the bleeding. Although the
tumour was identified in this case by CT angiography, a simple
contrast enhanced CT would almost certainly have demonstrated
this tumour adequately, given the typical CT appearance of GIST,
with significant contrast enhancement and heterogeneity.
Pathology—GIST of spindle cell type (Figs 3 and 4), 90mm in
size, with complete local excision. Mitotic count—3 per 5mm
square. CD117 (Fig. 5) and DOG1 (Fig. 6) positive staining giving
a prognostic group of moderate risk (Miettinen’s classification)
of progressive disease. It is widely accepted that Interstitial
Cells of Cajal (ICC) are pace maker cells of the gut and probable
progenitor cells of GIST. Hyperplasia of ICC can be seen in cases
with NF1, however, in this case this could not be shown in the
background bowel (Fig. 7).
Figure 1: Axial CT imaging. Large exophytic cavitating lesion arising from
jejunum with no evidence of active haemorrhage.
Figure 2: Coronal CT imaging. Large exophytic cavitating lesion arising from
jejunum with no evidence of active haemorrhage.
Figure 3: Low power H&E for tumour in relation to bowel mucosa.
Figure 4: Higher power view showing the spindle appearance of tumour cells.
Figure 5: Immunohistochemical positivity for CD117.
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Differential diagnosis
• GIST
• Lymphoma
• Schwannoma
• Leiomyoma
Treatment
4 Units packed red cell transfusion.
Laparatomy with resection of small bowel tumour and small
bowel anastomosis and resection of ischaemic large bowel and
large bowel anastomosis. Operative findings showed a large
small bowel tumour to the left of the midline, with multiple
hamartomatous lesions along the small bowel with a 6 cm
ischaemic segment of large bowel which had been adherent to
the tumour. Specimens were sent to pathology.
Outcome and follow up
This lady was discharged on the eighth post-operative day with
follow-up in the outpatient clinic 6 weeks after discharge. Her
case was discussed at the MDT which recommended moderate
risk GIST follow-up, which will consist of regular clinic follow-
up and imaging evaluation.
DISCUSSION
GIST are rare tumours of mesenchymal origin, most commonly
located in the stomach or small intestine. Symptoms may be
vague including abdominal pain, nausea, vomiting, alteration
in bowel habit or GI bleeding [1]. Treatment options include
surgical resection for localized lesions and neoadjuvant
treatment using tyrosine kinase inhibitors for advanced disease
[1]. Patients with advanced GIST in the context of NF1 do not
respond well to imatinib, since the NF1 mutation appears to be
the key driver, rather than KIT mutations as most commonly
observed. For this reason the consensus is to avoid giving adju-
vant imatinib to patients with NF1 related GIST. Unless of
course an imitinib sensitive mutation (e.g. KIT exon 11) is also
present, which has very rarely been described [2].
NF1 is an autosomal dominant disorder. Features include
café au lait spots and neurofibromata. Prevalence is 1 in 3000
people, with half of patients having a family history and half of
cases arising spontaneously. There are several associated con-
ditions including MEN2A, MEN2B, hereditary breast cancer and
GIST [3]. There are various reports in the literature of GIST in
association with NF1, although little is known about the exact
risk of developing GIST in NF1 patients. The prevalence of GIST
in NF1 is estimated at 3.9–25%, with a median onset of 49 years,
and multiple lesions can occur [1, 4]. An autopsy series has
documented a GIST in one-third of NF1 patients [5], and a
review paper noted that more than half of GISTs in NF1 were
incidental findings compared to one in five in patients without
NF1 [6].
Learning points/take home messages
• GIST is a known association with NF type 1.
• Presenting features may include abdominal pain, nausea,
vomiting, change in bowel habit or GI bleeding so it is import-
ant to consider GIST as a differential diagnosis in patients
with symptomatic NF1.
• If OGD is normal in cases of GI bleeding; CT angiography
should be considered to further evaluate the source.
• GIST should be discussed at a specialist MDT to allow for
optimum surveillance according to grade of tumour.
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Figure 6: Immunohistochemical positivity for DOG1.
Figure 7: MNF staining the epithelium of the bowel while is negative in tumour
cells.
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